Pradžia › Vilkligė › Koloradas
Vilkligė klinikiniai tyrimai Koloradas
8 tyrimai dėl Vilkligė ieško dalyvių vietose Koloradas.
Miestai Koloradas
Oficialus tyrimo tekstas (anglų kalba)
A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50719, Aurora
Renkami dalyviai3 fazė
Amžius 16 ir vyresni · Visoms lytims · Atnaujinta 2026-10-02 · NCT06617325Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- University of Colorado Denver, Aurora
Renkami dalyviai2 fazė
Amžius nuo 18 iki 100 · Visoms lytims · Atnaujinta 2026-10-01 · NCT05268289A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Denver Arthritis Clinic - Lowry, Denver
Renkami dalyviai2 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-10-01 · NCT07409181Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- University of Colorado Denver, Aurora
Renkami dalyviai3 fazė
Amžius nuo 12 iki 100 · Visoms lytims · Atnaujinta 2026-10-01 · NCT06133972A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Denver Arthritis Clinic, Denver
Renkami dalyviai3 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-25 · NCT07438496A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- University of Colorado Denver, Aurora
Renkami dalyviai1 fazė
Amžius nuo 18 iki 74 · Visoms lytims · Atnaujinta 2026-09-10 · NCT07085104A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- University of Colorado, Aurora
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-08-21 · NCT06570798A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants
- GSK Investigational Site, Aurora
Renkami dalyviai1 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 65 · Visoms lytims · Atnaujinta 2026-06-22 · NCT06576271Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.